Castle Biosciences, Inc.

Company is completing DecisionDx-Mesothelioma validation under CAP accredited / CLIA certified standard operating procedures; Company present and information being presented at this week’s International Mesothelioma Interest Group (IMIG) meeting

Data presented this weekend at the American Society of Clinical Oncology 2012 Annual Meeting shows the DecisionDx-Thymoma test to be superior to traditional histopathology in predicting the risk of metastasis of thymoma tumors

DecisionDx-Thymoma test is intended to significantly improve metastatic risk staging when paired with traditional histopathology in thymoma tumors

Further validation is needed, but studies indicate that the BAP1 gene predicts metastasis of ocular melanoma tumors